ACM Central Laboratory, a central lab specializing in safety and specialty testing for clinical trials, announced expansion of its business development team by more than 100%.
Rochester, New York -- April 4, 2005 -- ACM Central Laboratory, a central lab specializing in safety and specialty testing for clinical trials, announced expansion of its business development team by more than 100%. Overwhelming demand for ACM Central Laboratory Services by new and existing customers has led to this growth.
ACM Central Laboratory Services has added U.S. business development directors in the Northeast, Southeast and on the West Coast. Tim Robey, Scott Keddy, Tab Moore and James Naumann join ACM's team of talented professionals. Highly experienced, these directors bring extensive knowledge of the clinical development industry. Their experience includes operational, clinical and business development responsibilities within contract research organizations (CRO), central labs, and pharmaceutical and biotech companies. In addition to sales in their respective regions, the directors will be responsible for ongoing client communication and ensuring customer satisfaction.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.